Learn About Urothelial Cancer

What is the definition of Urothelial Cancer?
Urothelial cancer, also known as transitional cell carcinoma, affects the kidney (renal) pelvis or ureter (tube) that drains urine from the kidney to the bladder and/or the lining of the inside of the bladder. It is the most common form of bladder cancer and occurs more frequently in men and older adults. The cause of urothelial cancer is unknown; however, some suspected causes are chronic irritation of the kidney from pain medicines, exposure to manufacturing chemicals and dyes, smoking or other tobacco use, past radiation exposure, and parasitic infections.
Save information for later
Sign Up
What are the symptoms of Urothelial Cancer?
Symptoms of urothelial cancer include fatigue, unexplained weight loss, loss of appetite, anemia, constant back pain, flank pain, pelvic pain, urinary urgency, pain, burning, or discomfort when urinating, or blood in urine (hematuria).
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Urothelial Cancer?
Treatment for urothelial cancer includes surgery and chemotherapy. Bladder cancer can recur after treatment; therefore, long-term follow-up is necessary.
Who are the top Urothelial Cancer Local Doctors?
SP
Dr. S K. Pal
Oncology
Elite
Highly rated in
25
conditions
Oncology

Hoag Hospital Newport Beach

Newport Beach, CA 

S Pal is an Oncologist in Newport Beach, California. Dr. Pal has been practicing medicine for over 19 years and is rated as an Elite doctor by MediFind in the treatment of Urothelial Cancer. He is also highly rated in 25 other conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Urothelial Cancer, and Prostate Cancer. He is board certified in Medical Oncology and Internal Medicine and licensed to treat patients in California.

View Profile
AK
Dr. Ashish M. Kamat
Urology | General Surgery
Elite
Highly rated in
7
conditions
Urology
General Surgery

University Of Texas MD Anderson Cancer Center

Houston, TX 

Ashish Kamat is an Urologist and a General Surgeon in Houston, Texas. Dr. Kamat has been practicing medicine for over 28 years and is rated as an Elite doctor by MediFind in the treatment of Urothelial Cancer. He is also highly rated in 7 other conditions, according to our data. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Urachal Cancer, and Familial Prostate Cancer. He is board certified in Urology and licensed to treat patients in Texas. Dr. Kamat is currently accepting new patients.

View Profile
 
 
 
 
Learn about our expert tiers
Learn more
GD
Dr. Guido M. Dalbagni
Urology
Elite
Highly rated in
20
conditions
Urology

Memorial Sloan Kettering Bergen

Montvale, NJ 

Guido Dalbagni is an Urologist in Montvale, New Jersey. Dr. Dalbagni has been practicing medicine for over 43 years and is rated as an Elite doctor by MediFind in the treatment of Urothelial Cancer. He is also highly rated in 20 other conditions, according to our data. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Renal Cell Carcinoma, and Chromophobe Renal Cell Carcinoma. He is board certified in Urology and licensed to treat patients in New York. Dr. Dalbagni is currently accepting new patients.

View Profile
View All Doctors
What are the latest Urothelial Cancer Clinical Trials?
Comparative Study Between Ileal Conduit and Unilateral Cutaneous Ureterostomy With Separate Stomas Post Radical Cystectomy
Status: Not yet recruiting
Start Date: November 1, 2020
Intervention Type: Procedure
View Trial
Summary: Bladder cancer is the most common malignancy of the urinary tract and accounts for about 3.2% of all cancer worldwide where it remains the seventh most commonly diagnosed malignancy in the male population. Causative risk factors can be broadly divided into inherited and acquired due to environmental exposure ,Tobacco smoking is the most important environmental risk factor for bladder cancer(1).~Hi...
Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274)
Who is this study for: Patients with Various Advanced Cancer
Status: Active, not recruiting
Start Date: March 22, 2016
Intervention Type: Other, Biological
Study Drugs: Nivolumab
Phase: Phase 3
View Trial
Summary: The purpose of this study is to determine the effectiveness and safety of Nivolumab compared to placebo in participants who have undergone radical surgery for invasive urothelial cancer.
View All Clinical Trials
What are the Latest Advances for Urothelial Cancer?
Mycotic aortic aneurysm formation following intravesical BCG treatment for transitional cell carcinoma of the bladder.
Condition: Mycotic Aortic Aneurysm Following Intravesical BCG for Transitional Cell Carcinoma of Bladder
Journal: BMJ case reports
Treatment Used: Emergency Endovascular Aortic Aneurysm Repair and Anti-Tuberculosis Medication
Number of Patients: 1
Published: November 24, 2021
View publication
Summary: This case report describes a 72-year-old man who developed a mycotic aortic aneurysm following intravesical BCG treatment for transitional cell carcinoma of the bladder treated with emergency endovascular aortic aneurysm repair and anti-tuberculosis medication.
QUALITY OF LIFE IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER AFTER ORGAN-PRESERVING TREATMENT.
Condition: Muscle Invasive Bladder Cancer (MIBC)
Journal: Georgian medical news
Treatment Used: Organ-Preserving Treatment
Number of Patients: 120
Published: November 08, 2021
View publication
Summary: This study analyzed the quality of life for organ-preserving treatment in patients with muscle invasive bladder cancer (MIBC).
Tired of the same old research?
Check Latest Advances
Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma.
Condition: Pembrolizumab-Refractory Urothelial Carcinoma
Journal: Anticancer research
Treatment Used: Platinum-Based Chemotherapy Rechallenge
Number of Patients: 14
Published: November 04, 2021
View publication
Summary: This study investigated platinum-based chemotherapy rechallenge in the treatment of patients with pembrolizumab-refractory urothelial carcinoma.
View All Latest Advances